Recurrence of H Pylori : Incidence and Influential Factors.

Recurrence of H Pylori : Incidence and Influential Factors in Sohag Government.

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07045857

Enrollment

100

Registered

2025-07-01

Start date

2025-05-13

Completion date

2025-11-20

Last updated

2025-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H. Pylori Infection

Brief summary

This study aims to determine recurrence rates, identify influential factors, investigate key factors that contribute to recurrence, evaluate treatment effectiveness and to assess the efficacy of different eradication regimens and their role in reducing recurrence.

Interventions

BEHAVIORALfollow up of patients that had H. Pylori infection and recieved medical treatment for recurrence

follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence and influential factors for recurrence

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Age: 18-75 years old. * H. pylori infection: Confirmed by endoscopy, biopsy, or non-invasive tests (e.g., urea breath test, stool antigen test). * Symptoms: Presence of dyspepsia, peptic ulcer disease, or other H. pylori-related symptoms. * Laboratory tests: Normal liver and kidney function, and no significant abnormalities in blood counts.

Exclusion criteria

* Patients receiving eradication therapy in the past taking proton pump inhibitors,, H2 blockers ,,bismuth ,, antibiotics or other medications that interfere with the result of the examination in the recent 4 weeks. * Gastrointestinal disorders: Severe gastrointestinal disorders (e.g., gastric cancer, inflammatory bowel disease ,gastric or duodenal ulcer with current or recent bleeding , or clinical significant gastrointestinal bleeding within 4 weeks of randomization). * Malignancies: Active or recent malignancies. * Severe comorbidities: Unstable or severe comorbidities (e.g., heart failure, liver cirrhosis).

Design outcomes

Primary

Measure	Time frame	Description
recurrence of H. Pylori infection in patients who recieved medical treatment	4 weeks after successful medical treatment	H. Pylori antigen in stool

Countries

Egypt

Contacts

Primary ContactThomas W Thabet, Resident

thomaswagih0@gmail.com01286046059

Backup ContactUsama M Abdelaal, Professor

01065962094

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026